Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. We are pioneering novel T-cell reprogramming technologies designed to address major barriers to effective cell therapy for solid tumors.
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. We are pioneering novel T-cell reprogramming technologies designed to address major barriers to effective cell therapy for solid tumors.
Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, which represent approximately 90% of all cancers. At Lyell, our goal is to change that. We are a fully integrated company developing next-generation T-cell reprogramming technologies to overcome what we believe are the primary barriers to successful therapies in solid tumors: T-cell exhaustion and lack of durable stemness.
Our broad pipeline stems from our reprogramming technologies, which are designed to enhance the three main types of cell therapies: chimeric antigen receptor (CAR) T-cell therapy; tumor-infiltrating lymphocyte (TIL) therapy; and T-cell receptor therapy (TCR).
We have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products and clinically evaluating them in patients, all in our quest to defeat solid tumor cancers.
We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. The pursuit of scientific excellence and new discoveries continue to drive us forward.
We take an interrogative and cell biology-driven approach to our research. Our leaders have a wealth of scientific and operational expertise and experience translating research into therapies for patients, and we are aided by a digital analytics platform that allows us to be agile when translating insights into results.
We built our paperless, cGMP-qualified LyFE Manufacturing Center in Bothell, Washington to produce cell products at scale. Our in-house infrastructure gives us the ability to control the quality and supply of our products, and quickly adopt and incorporate new technologies.
Our researchers use advanced tools — including cloud computing and machine learning — for measuring and correlating cell activity remotely and in real time, with digital, paperless manufacturing supported by Amazon Web Services (AWS).
Our logo represents the three waves of curative therapies.
Mastery of small-molecule chemistry and the creation of the pharmaceutical industry
Mastery of proteins and macromolecules, and the creation of targeted therapies
Use of living cells as the definitive curative therapies for cancer
Our leaders are experts with proven track records of discovery and development of novel therapeutics.
Learn More